Search Results
Your search for ASCO matches 20849 pages
Showing 2801 - 2850Researchers Find Changes in Blood Proteins up to 2 Years Before Breast Cancer Diagnosis
Researchers have found changes in the levels of particular proteins in patients’ blood up to 2 years before they were diagnosed with breast cancer, according to a novel study published by Hagenaars et al in the European Journal of Cancer. The study, also presented at the 13th European Breast Cancer ...
Gradual Increase in Daily Activity With Psychological Therapies May Improve Mental and Physical Health for Patients and Survivors of Breast Cancer
Patients and survivors of breast cancer may have better mental health, physical health, and quality of life when taking part in a “behavioral graded activity” in combination with psychological therapies, according to a new study published by Lahousse et al in the European Journal of Cancer. The new ...
FDA Approves New Dosing Regimen for Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn
On November 18, the U.S. Food and Drug Administration (FDA) approved a new Monday/Wednesday/Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze). Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings and 50 mg/m2...
Study Examines Potential Factors Leading to Recurrence of Cancers Caused by BRCA Mutations
Researchers have discovered the factors that may make breast and ovarian cancers associated with BRCA1 and BRCA2 gene mutations more likely to recur, according to new findings published by Shah et al in Nature Communications. These mutations are known to strongly predispose women to breast and...
CAR T-Cell Therapy Outcomes Similar Across Different Socioeconomic Levels Among Patients With Pediatric ALL
Although socioeconomic status often influences survival outcomes, pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who were living in poverty and were treated with CAR T-cell therapy achieved similar overall survival and were equally likely to achieve a complete...
Moderate Exercise May Help Reduce Inflammation, Increase Survival in Patients With Colorectal Cancer by Improving Gut Microbiota
After examining the impact of exercise on the gut microbiome of patients with cancer and reporting a positive association, researchers discovered that regular physical activity may extend the survival of patients with colorectal cancer, according to a new study published by Himbert et al in the...
Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment
For many patients who have smoldering myeloma, early treatment can slow or delay the disease’s progression to multiple myeloma, according to a new study published by Sklavenitis-Pistofidis et al in Cancer Cell. Investigators demonstrated that changes in immune system cells may indicate which cases...
Prophylactic Bilateral Mastectomy Among Women With Breast Cancer and Pathogenic Variants in High-Penetrance and Moderate-Penetrance Genes
In a study reported in JAMA Oncology, Reid et al found that undergoing prophylactic bilateral mastectomy was as common in women with breast cancer with pathogenic/likely pathogenic variants in ATM and CHEK2 (moderate-penetrance genes) as in those with variants in BRCA1, BRCA2, or PALB2...
Antoni Ribas, MD, PhD, on Solid Tumors: Safety and Efficacy of TCR T-Cell Therapy
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, discusses a phase I study that used CRISPR gene editing to simultaneously “knock out” endogenous T-cell receptors and replace them with personalized neoantigen T-cell receptors in patients with solid tumors. The edited TCR T-cell...
Michael A. Postow, MD, on Using the Novel Radiotracer Crefmirlimab Berdoxam for Imaging to Assess Immunotherapy Responsiveness
Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings on the correlation between CD8 cell PET imaging with zirconium-89–crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. Noninvasive CD8 PET scanning...
David Reardon, MD, on Glioblastoma: A Microbiome-Based Vaccine, Nivolumab, and Bevacizumab
David Reardon, MD, of Dana-Farber Cancer Institute, discusses phase I/II results from the EOGBM1-18/ROSALIE study, which showed the EO2401 vaccine plus nivolumab generated systemic immune responses correlating with efficacy in patients with recurrent glioblastoma. Adding bevacizumab to this...
Wade T. Iams, MD, on NSCLC: Combining an Antigen-Presenting Cell Activator With Pembrolizumab
Wade T. Iams, MD, of Vanderbilt University Medical Center, discusses phase II efficacy results from the first-line non–small cell lung cancer cohort of the TACTI-002 study. The results suggest that when combined with pembrolizumab, eftilagimod alpha yielded encouraging efficacy across all PD-L1...
2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives
The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined ...
Used as a Biomarker, MicroRNA May Help Predict Which Patients With Breast Cancer Are More Likely to Have Cancer Recurrence
MicroRNA may be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to a new study published by Davey et al in the Journal of the American College of Surgeons. While long-term outcomes have improved for patients with breast cancer, 20%...
Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors
Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living with HIV and metastatic non–small cell lung cancer, who are often underrepresented in clinical...
New Research Highlights Disparities in Receipt of Guideline-Concordant Treatment Among Patients With Ovarian Cancer
New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...
Nationwide Study Finds Higher Rates of Cancer Mortality, Increasing Cases of Early-Onset Colorectal Cancer Among American Indian and Alaska Native Individuals
New findings revealed that overall cancer mortality among American Indian and Alaska Native patients was 18% higher than among White patients despite similar cancer incidence, according to a new study published by Kratzer et al in CA: A Cancer Journal for Clinicians. The findings included the first ...
Researchers Identify Subset of Patients With Stage I Melanoma Who Have Low Risk of Melanoma Mortality
Researchers identified a subset of patients who had early-stage melanoma with almost no melanoma-related deaths, potentially representing cases contributing to overdiagnosis, according to a new study published by Eguchi et al in Cancer. The findings may help clinicians determine which patients have ...
Cancer Clinical Trial Participation Among Medicare Fee-for-Service Beneficiaries With Cancer
In a retrospective cohort study reported in JAMA Oncology, Green et al found that only 1% to 2% of Medicare fee-for-service beneficiaries aged ≥ 65 years with cancer were enrolled in interventional cancer clinical trials. Study Details The study assessed clinical trial participation among patients...
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received...
New Phase I/II Data on the CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma
New data from an ongoing phase II trial evaluating first-line intratumoral administration of sotigalimab, a CD40 agonist antibody, in combination with systemic pembrolizumab, an anti–PD-1 antibody, in metastatic melanoma was presented by Bentebibel et al at the Society for Immunotherapy of Cancer...
Potential Treatment Options for Patients With Relapsed Multiple Myeloma Following CAR T-Cell Therapy
Researchers have identified potential therapies to treat patients with multiple myeloma whose cancer has relapsed following chimeric antigen receptor (CAR) T-cell therapy, according to a novel study published by Van Oekelen et al in Blood. CAR T-cell therapy has been a revolutionary treatment for...
Hormone Therapy May Lower Risk of Immune Checkpoint Inhibitor–Associated Myocarditis in Female Patients
Researchers may have discovered the underlying cause of sex differences in immune checkpoint inhibitor–associated myocarditis after immune checkpoint inhibitor treatment, according to a novel study published by Zhang et al in Science Translational Medicine. Their findings pointed to possible...
FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC
On November 10, the U.S. Food and Drug Administration (FDA) approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer (NSCLC) with no EGFR mutations or ALK genomic tumor aberrations. ...
FDA Approves Brentuximab Vedotin in Combination With Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma
On November 10, the U.S. Food and Drug Administration (FDA) approved the CD30-directed antibody-drug conjugate brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged 2 years and older with previously...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main takeaway is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to...
Expert Point of View: Glenn J. Hanna, MD, and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology
Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...
Eytan Stein, MD, Appointed Chief of the Leukemia Service at MSK
Eytan M. Stein, MD, will assume the role of Chief of the Leukemia Service in the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSK), New York. Dr. Stein joined MSK as a medical oncology/hematology fellow in 2010, became a faculty member in 2013, and was appointed...
SWOG Names Don S. Dizon, MD, Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity
After nearly a year-long search, the Southwest Oncology Group (SWOG) has announced its new Vice Chair for Diversity, Equity, Inclusion (DEI), and Professional Integrity: Don S. Dizon, MD, who is currently Chair of the organization’s Digital Engagement Committee. Dr. Dizon is Director of the Pelvic...
Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...
ASCO Releases Updated Resource-Stratified Guideline for the Secondary Prevention of Cervical Cancer
A new resource-stratified ASCO guideline update provides new evidence-based recommendations for the secondary prevention of cervical cancer in various resource settings.1 In the updated guideline, the screening recommendations cover basic, limited, enhanced, and maximal resource settings. Since...
Study Sheds Light on Need for Optimal Dosing Standards for Patients With Metastatic Cancer
A new study, published recently in JCO Oncology Practice, found that oncologists have different perspectives on how to select starting doses for patients with metastatic cancer.1 The study shared findings from a 2021 international survey of 367 medical oncologists who treat patients with metastatic ...
ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA
An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...
UChicago Medicine Names New Associate Director of Cancer Prevention and Population Sciences
Jasmin A. Tiro, PhD, MPH, has joined the University of Chicago Medicine Comprehensive Cancer Center as the new Associate Director of Cancer Prevention and Population Sciences. Dr. Tiro was formerly Professor of Population and Data Sciences at Harold C. Simmons Comprehensive Cancer Center at The...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
Erica Huelsmann, MD, Wins a Conquer Cancer Annual Meeting Merit Award
Erica Huelsmann, MD, a gynecologic oncology fellow at Fox Chase Cancer Center, Philadelphia, has been awarded a 2022 Conquer Cancer Merit Award by Conquer Cancer, the ASCO Foundation. The award, given at the 2022 ASCO Annual Meeting, supports researchers with projects that span many areas of...
I’ve Had Two Primary Lung Cancers, and They Haven’t Defeated Me
I don’t know why I am so susceptible to developing lung cancer. Since 2014, I have been diagnosed with both non–small cell lung cancer (NSCLC) and small cell lung cancer, each occurring in my right lung. I have also been diagnosed with precancerous colon polyps, which necessitated invasive surgery. ...
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain...
HPV Vaccine ‘Works Astonishingly Well’
The human papillomavirus (HPV) vaccine “works astonishingly well. It really prevents the kind of infections that cause cancer,” commented Ruanne Barnabas, MBChB, MSc, DPhil, MD, PhD, in an interview with The ASCO Post. “Other viral infections are difficult to protect against, or there might be...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
The Evolving Role of PI3K Inhibitors in Double-Refractory CLL
The treatment paradigm for chronic lymphocytic leukemia (CLL) continues to evolve in the first-line setting and beyond, with the availability of Bruton’s tyrosine kinase (BTK) inhibitors, the BCL2 inhibitor venetoclax, and novel combinations of these agents with anti-CD20 monoclonal antibodies....
NCI Honors Augusto Ochoa, MD, for Contributions to Community-Based Cancer Clinical Trials
The National Cancer Institute (NCI) chose Augusto Ochoa, MD, of Louisiana State University (LSU) Health, as the 2022 recipient of the Harry Hynes Award for Outstanding Contributions to Clinical Trials and Community Research. The award was presented during the NCI Community Oncology Research Program ...
Pediatric Surgeon Henri R. Ford, MD, Chosen New President-Elect of American College of Surgeons
Pediatric surgeon and surgeon-scientist Henri R. Ford, MD, MHA, FACS, FRCS, FAAP, has been chosen as President-Elect of the American College of Surgeons during the organization’s recent annual business meeting of members. The First Vice-President-Elect, Tyler G. Hughes, MD, FACS, and Second...
New Directions for Cancer Care: Major Trends in U.S. Health Policy
The pace of cancer drug development may have accelerated over the past decade, but so too has the cost of care, which threatens to limit access for a large percentage of Americans in the decade to come. During the keynote lecture at the 2022 ASCO Quality Care Symposium, Ezekiel J. Emanuel, MD, PhD, ...
Integrative Approaches to Managing Pain in Patients With Cancer: SIO-ASCO Guideline
Pain is highly prevalent in people with cancer throughout the disease trajectory. Often persisting for years after initial diagnosis and undertreated, it is associated with poor functional, mental, and cancer-related outcomes.1 Consequently, the need for effective pain management strategies has...
Study Finds Nearly Half of Black Women With Metastatic Breast Cancer Never Receive Information About Clinical Trial Participation
When Stephanie L. Walker, RN, was diagnosed with metastatic breast cancer in 2015, she was not given information about an appropriate clinical trial or help navigating her way through the financial difficulties she was having after a stroke from complications of the cancer forced her to leave her...
How to Advance Antiracist Approaches to Patient Engagement in AYA Oncology and Research
Among the topics discussed at the 4th Global Adolescent and Young Adult Cancer Congress held online in December 2021 was the urgent need for clinicians, researchers, and advocates in adolescent and young adult (AYA) oncology to join forces to eradicate racist approaches to patient engagement in...
